Will Dynamics Change for FOBs with Big Pharma in the Mix?
By Donna Young
Monday, March 2, 2009
There is little argument that follow-on biologics (FOBs) legislation to create an FDA approval pathway for the products will make its way through Congress this year, despite what is sure to be a political fight over the number of years of data exclusivity for innovator products.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.